Related Experiment Video
Updated: May 23, 2025

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
Published on: December 16, 2022
Cardiac Contractility Modulation Therapy and Device Algorithm-related Challenges
Farman Ali1, Khurram Arshad1, Rabia Latif2
1Department of Cardiology, Corewell Health Dearborn Hospital, Dearborn, MI, USA.
Insights
Cardiac contractility modulation (CCM) offers a promising treatment for heart failure with reduced ejection fraction (HFrEF). This article emphasizes the need for provider training and a troubleshooting algorithm to optimize CCM device management for better patient outcomes.
Area of Science:
- Cardiology
- Biomedical Engineering
Background:
- Heart failure (HF) is a critical condition with high morbidity, mortality, and reduced quality of life.
- HF with reduced ejection fraction (HFrEF) significantly impacts patients' functional capacity and healthcare costs.
- Cardiac contractility modulation (CCM) is an emerging device-based therapy for HFrEF.
Abstract:
Heart failure (HF) is a complex and potentially life-threatening medical condition posing significant risks to individuals. It is associated with substantial health care expenditures, considerable morbidity and mortality, and a decline in functional capacity and quality of life. Cardiac contractility modulation (CCM) has emerged as a promising device-based treatment for patients with HF with reduced ejection fraction (HFrEF). Studies have shown that CCM treatment in HFrEF patients can improve exercise tolerance and quality of life and reduce HF hospitalizations. As CCM therapy becomes a more prevalent treatment for HFrEF, the natural learning curve inherent in the use of new technologies necessitates broader provider training and careful patient follow-up. To that end, this article highlights the importance of developing a fundamental troubleshooting algorithm to help optimize the management of patients who have an implanted CCM device.
Related Concept Videos
Pathophysiology of Cardiac Performance
Heart Failure Drugs: Inotropic Agents

